

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

Supplementary Materials


Supplementary Table S1: Multivariate analyses including BRCA1/2-mutation status and neoantigen load in the TCGA dataset

| Factor | HR | Cox <i>p</i> |
|--|-------------------------------|--------------|
| BRCA1/2-mutated vs rest | 0.479, 95% C.I. = 0.308–0.745 | 0.001 |
| Neoantigen load (low quartile vs rest, cut-off 27) | | 0.232 (NS) |


| Factor | HR | Cox <i>p</i> |
|--|-------------------------------|--------------|
| BRCA1/2-mutated vs rest | 0.478, 95% C.I. = 0.308–0.741 | 0.001 |
| Neoantigen load (low quintile vs rest, cut-off 25) | | 0.13 (NS) |

Supplementary Table S2: Antibodies used in the study

| Antibody | Company | Clone | Dilution | Antigen Retrieval Buffer |
|----------|----------------|--------------------|----------|--------------------------|
| CD3 | Dako | A0452 (polyclonal) | 1:250 | H2 |
| CD4 | Dako | M7310 (4B12) | 1:80 | H2 |
| CD8 | Dako | M7103 (C8/144B) | 1:100 | H2 |
| CD20 | Dako | M0755 (L26) | 1:500 | H1 |
| PD-1 | Cell Marque | 315 m-95 (NAT105) | 1:300 | H2 |
| PD-L1 | Cell Signaling | 13684 (E1L3N) | 1:200 | H2 |



Supplementary Figure S1: Spearman correlation of CD3 and CD8 (A) and CD3 and PD-1 (B).



Supplementary Figure S2: Disease free survival for tumors with ≥ 13 CD3+ TILs/HPF versus tumors with < 13 CD3+ TILs per HPF.